Advances in the structural understanding of Vif proteins

Current HIV Research

Volumn 6, Issue 2, 2008, Pages 91-99

  Barraud, Pierre ^a   Paillart, Jean Christophe ^b   Marquet, Roland ^b   Tisné, Carine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INST DE BIOL MOLEC ET CELLULAIRE   (France)

Author keywords

APOBEC3G; Cullin5; Elongin; Reverse transcription; RNA; Vif protein

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CAPSID PROTEIN; CULLIN; CULLIN5; ELONGIN B; ELONGIN C; GENOMIC RNA; SUPPRESSOR OF CYTOKINE SIGNALING; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS RNA; ZINC BINDING PROTEIN;

AMINO ACID SUBSTITUTION; BINDING AFFINITY; GENETIC CONSERVATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MIMICRY; MUTAGENESIS; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RESIDUE ANALYSIS; REVIEW; RNA BINDING; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRUS INFECTIVITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 2; METABOLISM; PROTEIN TERTIARY STRUCTURE; SIMIAN IMMUNODEFICIENCY VIRUS;

AMINO ACID MOTIFS; GENE PRODUCTS, VIF; HIV-1; HIV-2; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 41249100869     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783885056     Document Type: Review

References (88)

1. Strebel K. HIV accessory genes Vif and Vpu. Adv Pharmacol 2007; 55: 199-232.
2. Fan L, Peden K. Cell-free transmission of Vif mutants of HIV-1. Virology 1992; 190: 19-29.
3. Gabuzda DH, Lawrence K, Langhoff E, et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992; 66: 6489-6495.
4. Borman AM, Quillent C, Chameau P, Dauguet C, Clavel F. Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol 1995; 69: 2058-2067.
5. Courcoul M, Patience C, Rey F, et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type I particles which are restricted for the preretrotranscription steps. J Virol 1995; 69: 2068-2074.
6. Sova P, Volsky DJ. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol 1993; 67: 6322-6326.
7. von Schwedler U, Song J, Aiken C, Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67: 4945-4955.
8. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
9. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9: 1398-1403.
10. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 2007; 32: 118-128.
11. Khan MA, Kao S, Miyagi E, et al. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 2005; 79: 5870-5874.
12. Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 2007; 3: e15.
13. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004; 18: 2867-2872.
14. Kao S, Khan MA, Miyagi E, et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging ofAPOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003; 77: 11398-11407.
15. Mariani R, Chen D, Schrofelbauer B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114: 21-31.
16. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12: 591-601.
17. Newman EN, Holmes RK, Craig HM, et al. Antiviral function of AP0BEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005; 15: 166-170.
18. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 2007; 282: 2587-2595.
19. Kawakami T, Sherman L, Dahlberg J, et al. Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. Virology 1987; 158: 300-312.
20. Oberste MS, Gonda MA. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 1992; 6: 95-102.
21. Tian C, Yu X, Zhang W, et al. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006; 80: 3112-3115.
22. Fujita, M, Akari H, Sakurai A, et al. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect 2004; 6: 791-798.
23. Xiao Z, Ehrlich E, Yu Y, et al. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006; 349: 290-299.
24. Mehle A. Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006; 281: 17259-17265.
25. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 2000; 74: 8938-8945.
26. Zhang H, Pomerantz RJ, Dornadula, G, Sun Y. Hurykan immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and-packaging process. J Virol 2000; 74: 8252-8261.
27. Khan MA, Aberham C, Kao S, et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol 2001; 75: 7252-7265.
28. Henriet S, Richer D, Bernacchi S, et al. Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J Mol Biol 2005; 354: 55-72.
29. Khan MA, Akari H, Kao S, et al. Intravirion processing of the human inummodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol 2002; 76: 9112-9123.
30. Hutoran M, Britan E, Baraz L, et al. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology 2004; 330: 261-270.
31. Yang X, Goncalves J, Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem 1996; 271: 10121-10129.
32. Yang X, Gabuzda D. Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. J Biol Chem 1998; 273: 29879-29887.
33. Yang S, Sun Y, Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem 2001; 276: 4889-4893.
34. Auclair JR, Green KM, Shandilya S, et al. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 2007; 69: 270-284.
35. Yang B, Gao L, Li L, et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type I (HIV-1) Vif proteins. J Biol Chem 2003; 278: 6596-6602.
36. Miller JH, Presnyak V, Smith HC. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology 2007; 4: 81.
37. Balaji S, Kalpana, R, Shapshak P. Paradigm development: comparative and predictive 3D modeling of HIV-1 Virion Infectivity Factor (Vif). Bioinformation 2006; 1: 290-309.
38. Lv W, Liu Z, Jin H, et al. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org Biomol Chem 2007; 5: 617-626.
39. Liu B, Yu X, Luo K, Yu Y, Yu XF. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004; 78: 2072-2081.
40. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cu15-SCF complex. Science 2003; 302: 1056-1060.
41. Mehle A, Strack B, Ancuta P, et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004; 279: 7792-7798.
42. Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003; 13: 2009-2013.
43. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 2004; 101: 3770-3774.
44. Mangeat B, Turelli P, Liao S, Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 2004; 279: 14481-14483.
45. Schrofelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 2004; 101: 3927-3932.
46. Xu H, Svarovskaia ES, Barr R, et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 2004; 101: 5652-5657.
47. Huthoff H, Malim MH. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 2007; 81: 3807-3815.
48. Li J, Potash MJ, Volsky DJ. Functional domains of APOBEC3G required for antiviral activity. J Cell Biochem 2004; 92: 560-572.
49. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cu15-ElonB/C E3 ubiquitin ligase. J Virol 2005; 79: 9579-9587.
50. Iwatani Y, Takeuchi H, Strebel K, Levin JG. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 2006; 80: 5992-6001
51. Gallois-Montbrun S, Kramer B, Swanson CM, et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol 2007; 81: 2165-2178.
52. Simon V, Zennou V, Murray D, et al. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role ih HIV-1 diversification. PLoS Pathog 2005; 1: e6.
53. Santa-Marta M, Aires da Silva F, Fonseca A, Goncalves J. HIV-1 Vif can directly inhibit APOBEC3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem 2005; 280: 8765-8775.
54. Wichroski MJ, Ichiyama K, Rana TM. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem 2005; 280: 8387-8396.
55. Schrofelbauer B, Senger T, Manning G, Landau NR. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 2006; 80: 5984-5991.
56. Mehle A, Wilson H, Zhang C, et al. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007; 81: 13235-13241.
57. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007; 81: 8201-8210.
58. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004; 18: 2861-2866.
59. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-467.
60. Pintard L, Willems A, Peter M. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J 2004; 23: 1681-1687.
61. Xiao, Z, Xiong Y, Zhang W, et al. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol 2007; 373: 541-550.
62. Luo K, Xiao Z, Ehrlich E, et al. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci USA 2005; 102: 11444-11449.
63. Krishna SS,, Majumdar I, Grishin NV. Structural classification of zinc fingers: survey and summary. Nucleic Acids Res 2003; 31: 532-550.
64. Paul I, Cui J, Maynard EL. Zinc binding to die HCCR motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci USA 2006; 103: 18475-18480.
65. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. Zinc chelation inhibits HIV Vif activity, and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 2007; 21: 217-222.
66. Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol 1999; 73: 2675-2681.
67. Kamura T, Sato S, Haque D, et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998; 12: 3872-3881.
68. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Nat Acad Sci USA 1999; 96: 2071-2076.
69. Kile BT, Schulman BA, Alexander WS, et al. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002; 27: 235-241.
70. Stebbins CE, Kaelin WG, Jr., Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999; 284: 455-461.
71. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 2005; 280: 18573-18578.
72. Simon JH, Carpenter EA, Fouchier RA, Malim MH. Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol 1999; 73: 2667-2674.
73. Poole E, Strappe P, Mok HP, Hicks R, Lever AM. HIV-1 Gag-RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET. Traffic 2005; 6: 741-755.
74. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J Biol Chem 2007; 282: 26361-26368.
75. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002; 415: 88-92.
76. Bardy M, Gay B, Pebernard S, et al. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: coencapsidation and interference with viral protease-mediated Gag processing. J Gen Virol 2001; 82: 2719-2733.
77. Levin JG, Guo J, Rouzina I, Musier-Forsyth K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol 2005, 80: 217-286.
78. Tisne C. Structural bases of the annealing of primer tRNA(3Lys) to the HIV-1 viral RNA. Curr HIV Res 2005; 3: 147-156.
79. Barraud P, Gaudin C, Dardel F, Tisne C. New insights into the formation of HIV-1 reverse transcription initiation complex. Biochimie 2007; 89: 1204-1210.
80. Henriet S, Sinck L, Bec G, et al. Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res 2007; 35: 5141-5153.
81. Liu H, Wu X, Newman M, et al. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol 1995; 69: 7630-7638.
82. Camaur D, Trono D, Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol 1996; 70: 6106-6111.
83. Dettenbofer M, Yu XF. Highly purified human immunodeficiency virus type I reveals a virtual absence of Vif in virions. J Virol 1999; 73: 1460-1467.
84. Kao S, Akari H, Khan MA, et al. Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol 2003; 77: 1131-1140.
85. Guo F, Cen S, Niu M, et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol 2007; 81: 11322-11331.
86. Li XY, Guo F, Zhang L, Kleiman L, Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem 2007; 282: 32065-32074.
87. Iwatani Y, Chan DS, Wang F, et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 2007.
88. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 1999; 292: 195-202.